Guest Feature - Antibody-drug conjugates: the new frontier of cancer treatments
Antibody-drug conjugates (ADCs) are transforming oncology, enabling highly targeted cancer treatments with fewer side effects compared to traditional chemotherapy.
By linking potent drugs to antibodies that seek out specific cancer cells, ADCs like Zynlonta have shown remarkable efficacy against previously untreatable cancers. With the global ADC market forecast to nearly triple by 2028, innovation continues across ADC components – antibodies, linkers, and warheads – driving breakthroughs such as dual-drug ADCs and advanced delivery mechanisms. Success in this competitive field requires experienced teams and robust intellectual property strategies. For a deeper exploration of ADC innovation and insights from expert Patrick van Berkel of ADC Therapeutics, read the full article.
Rapid advancements in linker technology, payload design, and tumour antigen selection have presented ADC innovators with a host of options to develop new therapies that improve patient outcomes. In that context, as a global pioneer in the ADC field, ADC Therapeutics’ experience in bringing such therapies to market offers valuable guidance to newer entrants to the field: assemble an experienced leadership team, focus on data-driven decision making, and secure your innovation with IP.
Robert Andrews
LET'S TALK
© 2025 Mewburn Ellis
